ABX
0.075
82.9%
AGN
0.28
-56.6%
KCCDA
1.04
55.2%
LML
0.006
-33.3%
4DX
1.155
50%
TMK
0.002
-33.3%
CTO
0.006
50%
1AD
0.003
-25%
M2R
0.003
50%
AYT
0.003
-25%
SNS
0.065
41.3%
SMM
0.012
-25%
8CO
0.04
33.3%
AX8
0.007
-22.2%
CTN
0.004
33.3%
ASP
0.008
-20%
MRQ
0.004
33.3%
BYH
0.004
-20%
TON
0.008
33.3%
COD
0.14
-17.6%
GIB
0.062
31.9%
ALM
0.005
-16.7%
CVB
0.14
27.3%
RLG
0.005
-16.7%
FLG
0.079
23.4%
EQR
0.035
-14.6%
ERL
0.006
20%
AKN
0.006
-14.3%
PGM
0.026
18.2%
COY
0.012
-14.3%
BUS
0.135
17.4%
MSG
0.006
-14.3%
TG1
0.034
17.2%
VML
0.185
-14%
ARV
0.007
16.7%
BMM
0.195
-13.3%
AZL
0.007
16.7%
GRE
0.052
-13.3%
BNL
0.007
16.7%
EQX
0.165
-13.2%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BlinkLab (ASX:BB1): Partners with US based

BlinkLab (ASX:BB1) has initiated a clinical study in partnership with US based Turning Pointe Autism Foundation.

The data obtained during the course of this collaboration will be used to finalise the data collection and processing algorithms as well as AI/ML models ahead of the FDA registrational study expected to start in the second half of 2024.

BlinkLab is an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism.

Read the ASX announcement: https://yourir.info/resources/3449d9aa01a61c6b/announcements/bb1.asx/6A1205872/BB1_BlinkLab_Partnership_with_Turning_Pointe_Autism_Foundation.pdf #BB1